Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04899999 · ClinicalTrials.gov registry record · NA
Graphic Messages to Prevent E-Cigarette Use Among Black and Latino Adolescents
A NA study, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 362
- Enrollment target
NCT04899999: Completed NA study, sponsored by University of Rochester.
NCT04899999 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 362 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04899999, a NA study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 362 participants
- Enrollment target
Study Summary
The aim of this study is to determine if graphic messages prevent future vaping use among African American and Latino adolescents. The images have been developed in a user-design model and include four main themes: health reward, financial reward, self-efficacy, and social norms. We will assess pre- and post-exposure reactions on likelihood of future vaping among African American and Latino adolescents.
Primary Outcome
Susceptibility to future vaping was assessed before and after exposure to the graphic messages. Informed by prior foundational research on youth electronic cigarette use, susceptibility was measured with three items assessing curiosity, intent, and social influence. Participants were asked, "Have you ever been curious about using e-cigarettes/vaping?", "Do you think that you will use e-cigarettes/vape in the next 12 months?", and "If one of your best friends were to offer you an e-cigarette/elec
Interventions
- BEHAVIORAL Financial reward graphic message
- BEHAVIORAL Health reward graphic message
- BEHAVIORAL Self-efficacy graphic message
- BEHAVIORAL Social norms graphic message
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2021-08-06 |
| Est. Completion | 2021-12-15 |
| Phase | NA |
What the finished NCT04899999 record still lists
NCT04899999 is an interventional study that assigns participants to a tested intervention. The registered 362 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 4 interventions - of which Financial reward graphic message is the first listed.
NCT04899999 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04899999 about?
NCT04899999 is a clinical study titled "Graphic Messages to Prevent E-Cigarette Use Among Black and Latino Adolescents". The aim of this study is to determine if graphic messages prevent future vaping use among African American and Latino adolescents. The images have been developed in a user-design model and include four main themes: health reward, financial reward, self-efficacy, and social norms. We will assess pre-...
What is the current status of trial NCT04899999?
This trial is currently completed. It is a NA study. The enrollment target is 362 participants. The study started on 2021-08-06. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT04899999?
The interventions under investigation include: Financial reward graphic message (BEHAVIORAL), Health reward graphic message (BEHAVIORAL), Self-efficacy graphic message (BEHAVIORAL), Social norms graphic message (BEHAVIORAL).
Who is sponsoring clinical trial NCT04899999?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04899999's enrollment target sits among peer trials
362 284th of 2000 higher than 1,717 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04988555 · 362 participants · Phase 1
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- NCT05536141 · 362 participants · Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- NCT06534983 · 362 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI